A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Osimertinib (Primary) ; Sapanisertib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 17 Oct 2016 Status changed from not yet recruiting to recruiting.
- 13 Oct 2016 Planned primary completion date changed from 1 May 2017 to 1 Apr 2018.
- 10 Oct 2016 Planned initiation date changed from 1 Oct 2015 to 1 Nov 2016.